Core & Trust
Editorial Standards
The rules a page has to clear before it ships
Thirteen gates stand between a draft and a published page. A draft that fails any one of them does not publish late, it does not publish partially — it does not publish.
Thirteen gates stand between a draft and a published page. A draft that fails any one of them does not publish late, it does not publish partially — it does not publish.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Search intent match | Does the page answer the question actually being asked? |
| 2 | Original value test | What exists here that is not already on ten other sites? |
| 3 | Source and evidence review | Every claim resolves to a ledger entry with a capture date. |
| 4 | Medical review | A named clinician checks claims against their primary sources. |
| 5 | Pricing verification | Figures re-captured from the provider's own page, dated. |
| 6 | Conflict-of-interest review | Any relationship that could bias the page, declared. |
| 7 | Legal and regulatory language | No implied approval, no generic claim, no individual advice. |
| 8 | Accessibility review | WCAG 2.2 AA, keyboard, contrast, chart data tables. |
| 9 | Mobile QA | 390px viewport hides no fee, qualifier, status or date. |
| 10 | Structured-data validation | JSON-LD matches what a reader can see. |
| 11 | Internal-link validation | Parent hub, methodology, siblings, tool or dataset. |
| 12 | Duplication and cannibalisation check | No two pages chasing the same intent. |
| 13 | Date and cadence assignment | Review dates set from real work, not from the calendar. |
| Area | Commitment | How you can check it |
|---|---|---|
| Every figure | Carries a source and a capture date | Open the provenance stamp beside it |
| Every clinical claim | Traced to a primary source | Follow the citation, not our summary |
| Every score | Computed from published inputs | Read the raw inputs on the provider page |
| Every correction | Dated and permanent | Read the corrections log |
| Every medical review | Dated on the page | Read “Last medically reviewed” in the byline |
A dash means no figure held. How we grade evidence.
The thirteen gates
The thirteen gates fall into four groups. A page has to clear all of them.
- Should this page exist? Gate 1, search intent match; gate 2, original value; gate 12, the duplication and cannibalisation check. If another page already answers the question, the draft is merged into it or dropped.
- Is it true? Gate 3, source and evidence review: every claim resolves to a dated ledger entry. Gate 4, medical review against primary sources. Gate 5, pricing verification on the seller's own page.
- Is it fair and accurately worded? Gate 6, the conflict-of-interest review. Gate 7, legal and regulatory language: no implied FDA approval, no generic claim, no individual advice.
- Does it work for every reader? Gate 8, accessibility to WCAG 2.2 AA, with data tables behind charts. Gate 9, mobile QA at a 390px viewport. Gate 10, structured data that matches the visible page. Gate 11, internal links to the parent hub, the methodology and related tools.
Gate 13 sets the next review date from the work actually done. A "last reviewed" date should mean someone re-checked the page.
Who signs off each gate
| Gate | Signed off by |
|---|---|
| 1, 2, 12: intent, original value, duplication | The editor responsible for the page |
| 3: source and evidence review | The researcher; clinical sources by Dr. Parmis, medical researcher |
| 4: medical review | A medical reviewer: Dr. Jonathan Snipes, MD, or Kim Callender, NP (FNP-BC) |
| 5: pricing verification | The pricing researcher, then a second reviewer who re-opens the source |
| 6: conflict of interest | The editor, before any reviewer credit appears |
| 7: legal and regulatory language | The editor, against the language list below |
| 8 to 11: accessibility, mobile, structured data, links | The editor publishing the page |
| 13: date and cadence | The editor responsible for the page |
One rule has no exception: the second reviewer on a price is never the person who first read it.
What happens when a gate fails
The page waits. A failed draft goes back to whoever owns the failed gate, with the reason written down, and it re-enters the sequence at that gate once fixed.
Common cases:
- A price cannot be read on the seller's own page. The figure is removed or marked pending capture. The page waits for a fresh read, or publishes without that number.
- A clinical claim does not match the trial publication. The claim is rewritten to match the source and goes back to medical review.
- A phrase implies FDA approval of a compounded product. It is rewritten, and the page goes back through gate 7.
- A conflict turns up. The conflicted person comes off the page and someone else repeats their step.
The same rules apply when a live page is re-reviewed. If a published page is found to fail a gate, it is fixed and, where a reader could have been misled, the change goes on the corrections log.
Language we do not use
| We do not write | We write instead |
|---|---|
| "FDA-approved compounded tirzepatide" | "compounded tirzepatide, which is not FDA-approved" |
| "generic Zepbound", "generic tirzepatide" | "compounded tirzepatide"; no generic tirzepatide exists |
| "identical to Zepbound", "the same as Zepbound" | "made with the drug in Zepbound, not the same product" |
| "cheapest", "best", "#1" with nothing attached | the plan type, dose, date and the rubric behind the claim |
| "you will lose 20%" | the trial, dose, duration and estimand behind a group average |
| "start at 2.5 mg, then move up to..." addressed to you | what the label or the trial protocol specified, and a prompt to ask your clinician |
When a provider's own page uses one of these phrases, we do not repeat it as fact. It counts against the provider under regulatory disclosure in the methodology.
Related on this site
- Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
- About Tirzepatide RankedCore & Trust
- Provider Ranking MethodologyCore & Trust
- Medical Review ProcessCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Evidence and Citation PolicyCore & Trust
- Tirzepatide and Fatty Liver / MASHResearch
- Tirzepatide and Diabetes Prevention Over 176 WeeksJournal
- Tirzepatide and Chronic Kidney DiseaseResearch
Related coverage
- ED Medication Online: Generic Prices, Compounded Claims and What Actually Differs
- Compounded tirzepatide price index
- What you pay at a maintenance dose
- MEDVi vs Yucca Health
- MEDVi vs Zappy Health
- Microdose vs Standard-Dose Tirzepatide
- Mochi Health vs Henry Meds
- Mochi Health vs NexLife
- Mochi Health vs Noom Med
Tirzepatide Ranked. “Editorial Standards.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/editorial-standards/
Quote the capture date beside a figure, not the date you read this page. Why.